Piracetam is the original racetam nootropic, synthesized in 1964 by Romanian chemist Corneliu Giurgea, who coined the term nootropic to describe it. It is a cyclic derivative of GABA but does not act on GABA receptors. Piracetam modulates AMPA and NMDA glutamate receptors, enhances membrane fluidity, and improves cerebral blood flow. It is one of the most extensively studied cognitive enhancers, with decades of clinical research supporting its use in age-related cognitive decline, dyslexia, and post-stroke recovery. Effects are subtle and cumulative, often requiring weeks of daily dosing to become apparent. It is widely available as a prescription medication in Europe and as a supplement elsewhere.
Harm Reduction
Piracetam is one of the safest nootropics available. For optimal use: Start with a standard dose of 1.2-2.4 g twice daily (total 2.4-4.8 g/day). Some users report needing a loading phase of higher dos...
Read full harm reduction guide